Protalix BioTherapeutics says the last patient has been enrolled in its Phase 2 study assessing AIR DNase in cystic fibrosis . Top-data should be available in the first week of January with complete result to follow by the end of Q1.
Protalix BioTherapeutics says the last patient has been enrolled in its Phase 2 study assessing AIR DNase in cystic fibrosis . Top-data should be available in the first week of January with complete result to follow by the end of Q1.